The earnings call highlights significant progress in clinical trials and financial management, with strong site engagement and promising data, particularly in the ALPHA3 and ALLO-316 programs. However, operational delays and financial losses present challenges. Overall, the sentiment reflects a balanced view with optimism for future achievements.

Company Guidance -

Q2 2025

During Allogene Therapeutics' first quarter 2025 conference call, the company provided detailed guidance on its clinical trials and financial outlook. The ALPHA3 trial aims to redefine treatment for large B cell lymphoma, with over 250 patients consented for MRD screening, nearly half within the last three months. The trial's lymphodepletion regimen selection and futility analysis milestone have been shifted to the first half of 2026, two quarters later than initially planned. Additionally, the ALLO-316 trial in advanced renal cell carcinoma shows promising efficacy, with an upcoming presentation at ASCO. The ALLO-329 RESOLUTION Trial, launching mid-2025, targets autoimmune diseases and proposes eliminating lymphodepletion. The company has extended its cash runway into the second half of 2027, thanks to a refined operational strategy and cost realignment. Financially, Allogene reported $335.5 million in cash, cash equivalents, and investments as of March 31, 2025. The R&D expenses were $50.2 million, with a net loss of $59.7 million for Q1 2025. The full-year 2025 cash burn is expected to be around $150 million, with operating expenses projected at $230 million.

Strong Site Engagement for ALPHA3 Trial

The ALPHA3 trial has seen significant site engagement, with nearly 50 activated U.S. sites and plans for international expansion. Over 250 patients have consented for MRD screening, with nearly half in the last three months.

Extended Cash Runway

Allogene has extended its cash runway into the second half of 2027, allowing it to navigate market headwinds and continue advancing its trials.

ALLO-316 Shows Promise in Solid Tumors

ALLO-316 continues to show efficacy in patients with advanced renal cell carcinoma, providing hope for heavily pretreated patients. The upcoming oral presentation at ASCO on June 1st is expected to showcase further results.

Advancements in Autoimmune Disease with ALLO-329

ALLO-329 is set to change the treatment of autoimmune diseases with its innovative design that could eliminate lymphodepletion. The RESOLUTION trial is expected to launch mid-2025.

Allogene Therapeutics (ALLO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ALLO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 13, 2025	2025 (Q2)	-0.27 / -	-0.35	―	―	―
May 13, 2025	2025 (Q1)	-0.29 / -0.28	-0.38	26.32% (+0.10)	―
Mar 13, 2025	2024 (Q4)	-0.33 / -0.28	-0.51	45.10% (+0.23)	―
Nov 07, 2024	2024 (Q3)	-0.33 / -0.32	-0.37	13.51% (+0.05)	―
Aug 07, 2024	2024 (Q2)	-0.35 / -0.35	-0.53	33.96% (+0.18)	―
May 13, 2024	2024 (Q1)	-0.41 / -0.38	-0.68	44.12% (+0.30)	―
Mar 14, 2024	2023 (Q4)	-0.45 / -0.51	-0.66	22.73% (+0.15)	―
Nov 02, 2023	2023 (Q3)	-0.52 / -0.37	-0.58	36.21% (+0.21)	―
Aug 03, 2023	2023 (Q2)	-0.59 / -0.53	-0.52	-1.92% (-0.01)	―
May 03, 2023	2023 (Q1)	-0.62 / -0.68	-0.56	-21.43% (-0.12)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ALLO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 13, 2025	$1.13	$0.95	-15.93%
Mar 13, 2025	$1.89	$1.94	+2.65%
Nov 07, 2024	$3.19	$3.08	-3.45%
Aug 07, 2024	$2.47	$2.36	-4.45%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Allogene Therapeutics (ALLO) report earnings?

Allogene Therapeutics (ALLO) is schdueled to report earning on Aug 13, 2025, Before Open (Confirmed).

What is Allogene Therapeutics (ALLO) earnings time?

Allogene Therapeutics (ALLO) earnings time is at Aug 13, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ALLO EPS forecast?

ALLO EPS forecast for the fiscal quarter 2025 (Q2) is -0.27.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing